Monsanto's plant protection team taps Complix NV for drug targeting knowhow
Agricultural technology firm Monsanto has partnered with Complix NV to develop the latter’s protein therapeutic targeting technology for crop protection applications.
Agricultural technology firm Monsanto has partnered with Complix NV to develop the latter’s protein therapeutic targeting technology for crop protection applications.
CMOs and Pharmas will own the manufacturing processes developed at a new facility as part of an ‘open source’ ethos Merck Millipore has introduced.
Cyprotex and InSphero have teamed up to offer predictive drug toxicity services using 3D micro-models of liver tissue.
Genetically modified corn could soon be used to mass-produce the enzymes used in rare-disease therapies, according to new research.